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acid peptide, is mainly synthesized in gastric mucosa and secreted to the bloodstream into two main forms: acylated ghrelin, with an n-octanoic acid at the Ser3 residue, and desacyl ghrelin, without this modification (20) (21) (22) . NAFLD is associated with alterations in total ghrelin concentrations (16, 18) . The progression of NAFLD to NASH results from numerous events originated in the liver and in extrahepatic drivers, such as an overload of nonesterified fatty acids (NEFAs) and proinflammatory adipokines derived from visceral adipose tissue as well as changes in gut microbiota that increase gut permeability to bacterial products triggering hepatic inflammation and fibrosis (23, 24) . Interestingly, ghrelin isoforms promote plasma NEFA storage within visceral adipose tissue by stimulating lipogenesis (25) and inhibiting lipolysis (26) . Moreover, both chronic central and peripheral administration of ghrelin stimulates hepatic triacylglycerol (TG) storage in vivo in rodents (27, 28) and regulates lipogenesis, mitochondrial NEFA b-oxidation, and autophagy in rat primary hepatocytes in vitro (12) . Additionally, acylated ghrelin treatment normalizes hepatic proinflammatory markers nuclear factor kB and TNF-a of obese rats, supporting its antiinflammatory role in the liver (29) . However, the specific role of acylated and desacyl ghrelin in the progression of NAFLD to NASH remains unclear in humans. Thus, our hypothesis was that ghrelin isoforms protect against the pathogenic role of TNF-a in the development of NASH through the regulation of hepatocyte cell death in a series of patients with morbid obesity classified according to their insulin resistance. We therefore sought to (1) explore the potential differences in circulating acylated and desacyl ghrelin as well as TNF-a concentrations in obesity-associated insulin resistance and NAFLD before and after weight loss induced by bariatric surgery; characterize ex vivo the hepatic expression of the ghrelin-ghrelin O-acyltransferase (GOAT) system, TNF protein superfamily members, as well as key regulatory molecules of hepatocyte cell death; and (3) analyze in vitro the effect of acylated and desacyl ghrelin on basal and TNF-a-induced apoptosis, autophagy, and HMGB1-mediated pyroptosis in human HepG2 hepatocytes.
Methods

Cross-sectional and interventional studies
Plasma ghrelin isoforms and TNF-a were evaluated in a cross-sectional study with 158 samples obtained from patients undergoing Nissen funduplication (n = 30, patients who were lean) or Roux-en-Y gastric bypass (RYGB) (n = 128, patients with obesity) at the Clínica Universidad de Navarra. Obesity was defined as a body mass index (BMI) $30 kg/m 2 , and normal weight as a BMI ,25 kg/m 2 . Patients with obesity were subclassified into three groups [normoglycemia (NG), impaired glucose tolerance (IGT), or T2D] following the criteria of the Expert Committee on the Diagnosis and Classification of Diabetes (30) . Inclusion criteria encompass a complete diagnostic workup, including physical examination, laboratory investigation, ultrasound echography, and a liver biopsy consistent with the diagnosis of NAFLD. Exclusion criteria were: (1) significant alcohol abuse (average daily alcohol consumption $20 g for women and $30 g for men); (2) the presence of hepatitis B virus surface antigen or hepatitis C virus antibodies in the absence of a history of vaccination; (3) use of medication associated with NAFLD within the past year, including amiodarone, valproate, tamoxifen, methotrexate, corticosteroids, or antiretrovirals; and (4) evidence of other specific liver diseases, such as autoimmune liver disease, hemochromatosis, Wilson disease, or a-1-antitrypsin deficiency evaluated by antinuclear antibody, smooth muscle antibody, ferritin, a-1-antitrypsin, and ceruloplasmin levels. Intraoperative liver biopsies were obtained from patients with obesity during RYGB to establish a histological diagnosis of the hepatic state, but this procedure is not clinically justified in subjects who were lean. In the interventional study, a group of patients with obesity (n = 73) was selected to investigate the impact of weight loss achieved 6 months after RYGB on circulating ghrelin and TNF-a. All reported investigations were carried out in accordance with the principles of the Declaration of Helsinki, as revised in 2013, and approved by the Hospital's Ethical Committee responsible for research (no. 061/2014). Written informed consent was obtained from all the participants.
Analytical procedures
Biochemical assays were performed as previously described (25, 31) . The adipocyte insulin resistance (Adipo-IR) index, as a surrogate of adipocyte dysfunction, was calculated as fasting NEFA (mmol/L) 3 fasting insulin (pmol/L). Acylated and desacyl ghrelin were determined by ELISA (no. EZGAC-86K and no. EZGDAC-87K, Linco Research, St. Charles, MO), with intra-assay and interassay coefficients of variation being 5.5% and 2.6%, respectively, for the former, and 4.7% and 4.2%, respectively, for the latter. TNF-a was measured with a highsensitivity ELISA (no. HSTAA00D, R&D Systems, Minneapolis, MN); intra-assay and interassay coefficients of variation were 5.0% and 5.7%, respectively.
Liver histological analyses
The diagnosis of NAFLD and NASH was established based on Brunt (32) criteria by an expert pathologist masked to all the results of the assays. Briefly, steatosis was scored as an estimate of the percentage of hepatocytes displaying fatty changes: 1, up to 5%; 2, 6% to 33%; 3, 34% to 66%; or 4, .66%. Lobular and portal inflammation was graded on a scale of three categories: 0, none; 1, mild; or 2, moderate to marked (Brunt grades 2 and 3). Hepatocellular ballooning, pericellular/perisinusoidal fibrosis, portal fibrosis, and cirrhosis were scored as (0) absent or (1) present. Intrahepatic TGs were also determined by enzymatic methods (12) .
The immunohistochemistry of ghrelin, GOAT, and HMGB1 was performed as described before (15, 31) . Liver sections (4 mm) were incubated overnight at 4°C with rabbit polyclonal anti-ghrelin (no. GHSR11-A, Alpha Diagnostic International, San Antonio, TX), anti-GOAT (no. sc-87999, Santa Cruz Biotechnology, Santa Cruz, CA), or anti-HMGB1 (no. NB100-2322, Novus Biologicals, Cambridge, UK) antibodies (dilution 1:50). After washing, slides were incubated with Dako Real EnVision HRP-conjugated anti-rabbit/mouse (Dako, Glostrup, Denmark) for 1 h at room temperature. Peroxidase reaction was visualized with a 3,3 0 -diaminobenzidine/H 2 O 2 solution, as chromogen, and Harris hematoxylin (Sigma-Aldrich, St. Louis, MO) as counterstaining.
The TUNEL assay was performed using an in situ cell death detection kit, POD (Roche, Basel, Switzerland) following the manufacturer's instructions. TUNEL-positive cells were analyzed under a light microscope.
Real-time PCR
Hepatic transcript levels of genes related to the ghrelin system [GHRL and membrane-bound O-acyltransferase (MBOAT)4], apoptosis (TNF, TNFR1, FAS, DR3), autophagy [PIK3C3, BECN1, autophagy-related gene (ATG) 5 and ATG7], and pyroptosis (HMGB1, TLR4, and RAGE) were quantified by real-time PCR (7300 real-time PCR system, Applied Biosystems, Foster City, CA) (33) . Primers and probes were designed using the software Primer Express 2.0 (Applied Biosystems) (Supplemental Table 1 ). All results were normalized to the levels of the ribosomal 18S rRNA (Applied Biosystems).
Western blot
Blots were incubated overnight at 4°C with anti-ghrelin (Alpha Diagnostic International), anti-GOAT (Santa Cruz Biotechnology), anti-procaspase-1, and anti-caspase-1 (no. 
Cell cultures
Human HepG2 hepatocytes (European Collection of Cell Cultures, Sigma-Aldrich) were seeded at 3 3 10 5 cells/cm 2 and grown in DMEM containing 10% fetal bovine serum, 25 mmol/L D-glucose, and 1% antibiotic/antimycotic (Invitrogen, Paisley, UK). Cells were serum starved for 24 hours and treated with increasing concentrations of acylated or desacyl ghrelin (nos. 1463 and 2260, Tocris, Ellisville, MO), TNF-a (no. 300-01A, PeproTech, Rocky Hill, NJ), or insulin (no. I5500, Sigma-Aldrich) for 24 hours. In a second subset of experiments, quiescent cells were incubated with TNF-a (100 ng/mL) in the presence/absence of acylated (100 pmol/L) or desacyl ghrelin (100 pmol/L) for 24 hours. In a third subset of experiments, cells were stimulated with acylated or desacyl ghrelin (100 pmol/L) in the presence of AMPK inhibitor compound C (20 mmol/L) (no. P5499, Sigma-Aldrich) or mTOR inhibitor rapamycin (10 mmol/L) (no. 1292, Tocris) for 24 hours. The concentrations of TNF-a, ghrelin isoforms, and pharmacological inhibitors were chosen on the basis of prior experiments performed in our laboratory (31, 34) .
Confocal immunofluorescence microscopy
Human HepG2 hepatocytes were exposed for 24 hours to insulin (100 nmol/L) or macrophage-conditioned medium (MCM) from THP-1 cells previously treated with 10 ng/mL lipopolysaccharide (LPS; MCM-LPS, 5%), as previously described (15) . Cells were fixed with 4% formaldehyde for 15 minutes at room temperature, incubated with PBS containing 0.1% saponin and 1% BSA for 1 hour at room temperature, and exposed to a rabbit polyclonal anti-HMGB1 (Novus Biologicals) or mouse monoclonal lysosomal-associated membrane protein 1 (LAMP-1) (Enzo Life Sciences, Madrid, Spain) antibodies (dilution 1:100 in PBS containing 0.1% saponin) overnight at 4°C. Thereafter, cells were washed with PBS and incubated with Alexa Fluor 488-conjugated donkey anti-rabbit IgG or rabbit antimouse IgG (Invitrogen) diluted 1:500 for 2 hours at room temperature. After washing, cells were examined under a TCS-SP2-AOBS confocal laser scanning microscope (Leica, Heidelberg, Germany). Images underwent a deconvolution process with Huygens Essential 2.4.4 software (Scientific Volume Imaging, Hilversum, Netherlands).
Statistical analysis
Data are expressed as mean 6 SEM. Differences between mean values were determined using a Student t test, x 2 test, and one-way ANOVA followed by Scheffé, Tukey, or Dunnett tests, where appropriate. Pearson correlation coefficients (r) and stepwise multiple linear regression analysis were used to analyze the association between variables. Receiver operating characteristic (ROC) curve with 95% CIs were also elaborated to establish the accuracy of ultrasonography findings in predicting the extent of liver steatosis evaluated in histological analyses (35) . A P value ,0.05 was considered statistically significant. Statistical analyses were performed using the SPSS 15.0 software.
Results
High prevalence of NAFLD and NASH in morbid obesity
Anthropometric and clinical variables of patients included in the study are shown in Table 1 . All patients with morbid obesity and T2D exhibited hepatic steatosis as evidenced by echography, being reduced to 73.8% and 75.7% in the NG and IGT groups, respectively (P , 0.0001). In all patients, ultrasonography was able to correctly identify steatosis as compared with the histological analysis. ROC curves were elaborated to analyze the sensitivity (incidence of true-positive results) and specificity (incidence of true-negative results) of the diagnostic performance of the ultrasound echography to detect different degrees of steatosis on histology of liver biopsies (Supplemental Fig. 1 ). Ultrasound echography detected more accurately moderate-severe steatosis ($33% on histology) with a sensitivity of 95.0% and specificity of 80.0% [areas under the ROC curve 0.682 (0.547 to 0.816)] than mild steatosis (6% to 33% on histology) with a sensitivity of 94.7% and a specificity of 75.8% [area under the ROC curve 0.606 (0.495 to 0.717)]. The histological findings to assess the severity of NAFLD and NASH in liver biopsies of patients with morbid obesity (n = 103) are illustrated in Supplemental Table 2 and Supplemental Fig. 2 . In our cohort of patients with morbid obesity, the prevalence of biopsy-proven NAFLD was higher (P , 0.05) in men (94.4%) than in women (82.6%). In the obese T2D group, only 3.0% exhibited a normal liver histology and 39.4% revealed simple steatosis, whereas 57.6% exhibited different degrees of NASH. Compared with the T2D group, the prevalence of NASH was lower (P , 0.05) in NG (50.0%) and IGT (56.3%) patients. Liver biopsies of the obese T2D group showed higher (P , 0.05) steatosis than that in individuals with obesity who were NG. No patient had evidence of established cirrhosis.
Changes in circulating ghrelin isoforms in patients who are obese with morbid obesity and NAFLD and NASH before and after bariatric surgery
Patients with morbid obesity showed decreased circulating acylated (obese, 5.3 6 0.5 pmol/L; lean, 8.3 6 0.8 pmol/L; P = 0.015) and desacyl ghrelin (obese, 37.5 6 2.4 pmol/L; lean, 68.2 6 9.4 pmol/L; P = 0.005), without changes in the acylated/ghrelin ratio (obese, 0.17 6 0.12; lean, 0.15 6 0.01; P = 0.596) compared with individuals who were lean (Fig. 1A, 1D , and 1G). Plasma desacyl ghrelin levels were increased in women compared with men in the normal-weight group (women, 81.3 6 8.7 pmol/L; men, 50.6 6 9.1 pmol/L; P , 0.05), but not in the individuals with obesity (women, 37.1 6 4.1 pmol/ L; men, 40.7 6 4.4 pmol/L; P = 0.499). This sexual dimorphism was not found in circulating acylated ghrelin of the normal-weight individuals (women, 8.5 6 1.6 pmol/L; men, 8.8 6 1.7 pmol/L; P = 0.828) or in the patients with morbid obesity (women, 5.1 6 0.7 pmol/L; men, 5.5 6 0.8 pmol/L; P = 0.662), which is in agreement with previous results (25) . No effect of IGT or T2D was observed on circulating acylated and desacyl ghrelin concentrations or the acylated/ghrelin ratio. The presence of NAFLD and NASH in patients with obesity was associated with lower (P , 0.01) desacyl ghrelin concentrations ( Fig. 1E ) and an increase (P , 0.05) in the acylated/desacyl ghrelin ratio (Fig. 1H ). After sex and age adjustment, ghrelin isoforms were negatively associated with markers of obesity (BMI and percentage body fat), whereas they were positively correlated with g-glutamyltransferase (g-GT) levels. Multiple linear regression analysis revealed that insulin resistance, as evidenced by the homeostasis model assessment (HOMA) index, was not a major determinant of circulating concentrations of ghrelin isoforms (Supplemental Table 3 ). Body fat contributed to plasma acylated and desacyl ghrelin variance after controlling for the effects of age and sex (models I, II, and III). Otherwise, plasma TNF-a (P , 0.01) contributed independently to 14.5% (P , 0.01) of plasma acylated ghrelin levels after controlling for the effects of age, sex, and body fat.
After an average 6-month postsurgical period, patients with morbid obesity undergoing RYGB experienced a profound decrease in body weight and whole-body adiposity (Table 2) , an improved lipid profile, and an increase in insulin sensitivity. Bariatric surgery patients also showed a decrease in g-GT levels. A significant decrease in plasma acylated and desacyl ghrelin levels as well as in the acylated/ghrelin ratio was observed after bariatric surgery (Fig. 1C, 1F, and 1I) . Interestingly, the change in both acylated and desacyl ghrelin after RYGB showed a negative association with g-GT levels (r = 20.53, P = 0.025 and r = 20.33, P = 0.040, respectively). Postsurgical acylated ghrelin values were also positively correlated with high-density lipoprotein cholesterol (r = 0.50, P = 0.042). Interestingly, no association was detected between postsurgical acylated and desacyl ghrelin values with body weight changes and glycemic index, suggesting that the observed changes are related to modifications in the lipid profile and liver damage.
Ghrelin and GOAT in human liver
The presence of ghrelin and its acylating enzyme, GOAT, was analyzed by immunohistochemistry, realtime PCR, and Western blot in 76 liver biopsies obtained from patients with obesity. A strong immunoreactivity Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, high-sensitivity C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; QUICKI, quantitative insulin sensitivity check index. a P , 0.05 vs patients with obesity who were NG. Figure 1 . Effect of insulin resistance and NAFLD on circulating and hepatic expression levels of ghrelin in patients with morbid obesity. Impact of weight loss achieved by RYGB is shown. (A, B, D , E, G, and H) Fasting plasma acylated (A and B) and desacyl (D and E) ghrelin as well as the acylated/desacyl ghrelin ratio (G and H) according to morbid obesity, the degree of insulin resistance, and hepatic function (C, F, and I). Comparison of plasma acylated (C) and desacyl (F) ghrelin as well as acylated/ghrelin ratio (I) before and after weight loss achieved by RYGB (evaluated 6 mo after surgery) in patients with morbid obesity. (J and K) Immunohistochemical detection of ghrelin (J) and GOAT (K) in human liver sections. Original magnification, 3100; scale bars, 50 mm. Bar graphs show the hepatic gene expression of ghrelin and GOAT according to the degree of insulin resistance (L) and hepatic function (M). The gene expression in liver obtained from obese NG patients was assumed to be 1. *P , 0.05, **P , 0.01, ***P , 0.001 vs volunteers who were lean and NG, or values before interventional studies.
for ghrelin and GOAT was found in hepatocytes, which showed macrovesicular steatosis ( Fig. 1J and 1K ). Consistent with echographic and anatomopathological data, intrahepatic TGs were higher in the liver biopsies obtained from insulin-resistant patients (10.8 6 2.1 mg/g tissue) compared with the insulin-sensitive individuals (9.0 6 1.6 mg/g tissue). Similar hepatic GHRL transcripts were found in patients with obesity regardless of their insulin resistance or hepatic function, but hepatic MBOAT4 mRNA was increased with T2D ( Fig. 1L and 1M) . A similar trend was observed for hepatic ghrelin and GOAT protein levels (Supplemental Fig. 3) . Interestingly, GHRL mRNA was negatively associated with HOMA (r = 20.42, P = 0.012), whereas MBOAT4 transcripts were positively associated with intrahepatic TG (r = 0.63, P = 0.005) and plasma NEFA (r = 0.58, P = 0.015).
Ghrelin isoforms decreased TNF-a-induced apoptosis in human hepatocytes
T2D was associated with increased circulating concentrations of well-known inflammatory markers, including TNF-a (Table 1) . Moreover, an upregulation of TNF-a as well as of death receptors TNF-R1 and DR3 was observed in the liver of patients with morbid obesity with T2D ( Fig. 2A) . When the patients with obesity were classified according to their hepatic function, higher TNFR1 mRNA levels were found in patients with NASH [normal liver, 5.7 6 1.4 arbitrary units (AUs); NAFLD, 6.7 6 1.7 AU; NASH, 12.4 6 2.7 AU; P , 0.05], without significant changes in TNF, DR3 and FAS transcript levels (all P . 0.05). Interestingly, a remarkable increase (P , 0.0001) in hepatic TNFR1 mRNA was found in patients with obesity and pericellular/perisinusoidal fibrosis (28.9 6 11.5 AU) compared with those without fibrosis (7.3 6 0.9 AU). Hepatocyte apoptosis was also markedly increased in patients with morbid obesity and T2D, as evidenced by increased cleavage of caspase-8 and caspase-3 as well as TUNEL-positive cells (Fig. 2B-2D ). As expected, the incubation of human HepG2 hepatocytes with TNF-a for 24 hours significantly increased (P , 0.05) the activation of caspase-8 and caspase-3, as well as hepatocyte apoptosis (Fig. 2E-2G ). The coincubation with acylated ghrelin, or, to a lesser extent, with desacyl ghrelin reduced TNF-a-induced cleavage of caspase-8 (P = 0.033 and P = 0.049, respectively) and caspase-3 (P = 0.023 and P = 0.019, respectively), as well as the hepatocyte apoptotic cell death (P , 0.0001 and P = 0.100, respectively) ( Fig. 2H-2J ).
The potential cross-regulation between ghrelin isoforms and TNF-a in human HepG2 hepatocytes was also determined. Ghrelin isoforms did not change the transcription of TNF and TNFR1 in hepatocytes (Supplemental Fig. 4A and 4B ). However, TNF-a treatment induced MBOAT4 gene expression at the higher concentrations of 10 and 100 ng/mL, without modifying GHRL mRNA levels (Supplemental Fig. 4C ).
Ghrelin reduced basal and TNF-a-induced autophagy in human hepatocytes
Autophagy, featured by an increased LC3B-II/I ratio associated to a decreased p62/SQSTM1 protein content (36) , was analyzed in the liver samples. The expression of genes involved in autophagosome nucleation and elongation, such as class III PI3K, beclin-1, ATG5, and ATG7, was also evaluated. The liver of patients with T2D exhibited an increase in PIK3C3 transcripts, but an increase in the LC3B-II/I ratio was only observed in the prediabetic state without changes in p62 (Fig. 3A-3C) . In TNF-a-treated HepG2 cells, the expression of major autophagic pathway genes was unaltered relative to the expression observed in control cells (Fig. 3D) . However, TNF-a stimulation increased the LC3B-II/I ratio together with a downregulation of p62 (P , 0.05) (Fig. 3E and  3F) . Interestingly, the coincubation with acylated ghrelin significantly reduced TNF-a-induced autophagy, as evidenced by the lower LC3B-II/I ratio and the higher p62 accumulation (Fig. 3G-3I ). Desacyl ghrelin exerted a mild inhibition of the autophagy triggered by TNF-a, but differences did not reach statistical significance. Because ghrelin regulates the autophagic flux in several metabolic tissues (37), we further explored the specific effect of the isoforms of the hormone on basal autophagy in hepatocytes. In ghrelin-treated HepG2 hepatocytes, ATG5 and ATG7 trancripts (both P , 0.05) and the LC3B-II/I ratio (P , 0.01) were markedly decreased, whereas p62 levels were upregulated (P , 0.05) (Fig. 4A-4C ). In contrast, the stimulation of HepG2 cells with desacyl ghrelin upregulated (P , 0.05) the expression of ATGs and the LC3B-II/I ratio, whereas p62 levels were downregulated (P , 0.05) (Fig. 4D-4F ). AMPK and mTOR are the best characterized positive and negative regulators, respectively, of autophagy (37) . In line with the previous results, desacyl ghrelin (P , 0.05) activated AMPK with a maximal phosphorylation of AMPK observed 2 minutes after desacyl ghrelin stimulation in HepG2 hepatocytes, with attenuation of the phosphorylation thereafter ( Fig. 4G and 4H) . Conversely, only acylated ghrelin increased (P , 0.05) mTOR activation/phosphorylation in HepG2 cells ( Fig.  4I and 4J ). The nonphosphorylated forms of AMPK and mTOR remained constant along time in HepG2 stimulated with ghrelin (P = 0.960 and P = 0.467, respectively) or desacyl ghrelin (P = 0.301 and P = 0.209, respectively). Specific cell-permeable chemical inhibitors of AMPK and mTOR were added to the culture media before the addition of ghrelin isoforms to further investigate the involvement of these transduction signals in autophagy. AMPK inhibitor, compound C, significantly reduced the desacyl ghrelin-induced increase in the LC3B-II/I ratio and normalized p62 expression (Fig. 4K and 4L) , whereas the mTOR inhibitor rapamycin blunted the upregulation of the LC3B-II/I ratio as well as the p62 downregulation induced by ghrelin in HepG2 hepatocytes ( Fig. 4M and 4N ).
Ghrelin isoforms reduced TNF-a-induced pyroptosis in human hepatocytes
The staining of alarmin HMGB1 in liver sections was observed predominantly in the nuclei of hepatocytes from subjects with obesity who were NG, whereas a strong HMGB1 cytoplasmic immunosignal was mainly observed in hepatocytes from patients with obesity, IGT, and T2D, but not in the nuclei (Fig. 5A) . HMGB1 mRNA and protein levels were decreased in patients with obesity and T2D (Fig. 5B and 5C ). Interestingly, both TLR4 and RAGE transcripts (Supplemental Fig. 5 ), the receptors of HMGB1, and active caspase-1 (Fig. 5D) , the downstream effector of HMGB1, were markedly increased in the liver of patients with T2D.
To gain more insight into the regulation of HMGB1, its subcellular localization was studied in HepG2 hepatocytes by confocal microscopy (Fig. 5E) . Under basal conditions, HMGB1 was present predominantly in the nuclei. Notably, the incubation of HepG2 cells with MCM-LPS, or especially with insulin, promoted cytosolic translocation of HMGB1 to vesicle compartments resembling lysosomes. In this regard, HMGB1 secretion is induced by stimuli triggering lysosome exocytosis (38) . Accordingly, the double labeling of HMGB1 and the lysosomal marker LAMP-1 in insulin-treated hepatocytes revealed a strong colocalization of both molecules in lysosomes (Fig. 5F ). Both insulin and TNF-a, the most abundant cytokine produced by macrophages in response to LPS, increased HMGB1 transcript levels ( Fig. 5G and 5H) .
The protective effects of ghrelin on HMGB1-induced pyroptosis were also investigated. Both ghrelin isoforms downregulated HMGB1 mRNA in HepG2 hepatocytes (Fig. 6A and 6B ). Acylated and desacyl ghrelin inhibited TNF-a-induced transcription of HMGB1 (P = 0.043 and P = 0.014, respectively) and caspase-1 activation (P = 0.040 and P = 0.044, respectively) in HepG2 cells ( Fig. 6C and 6D ). Basal caspase-1 activation was unaltered by both ghrelin isoforms (both P . 0.05) (Fig. 6D ).
Discussion
The main findings of the current study are that: (1) obesity-associated NAFLD is associated with an increased acylated/ghrelin ratio as well as higher hepatic apoptosis, pyroptosis, and an impaired autophagy; (2) acylated and desacyl ghrelin reduce TNF-a-induced apoptosis and pyroptosis mediated by HMGB1 in human hepatocytes; and (3) acylated ghrelin reduces basal and TNF-a-induced hepatocyte autophagy via AMPK/mTOR.
Our cohort confirmed the high prevalence of biopsyproven NAFLD and NASH found in morbid obesity (39) as well as the sexual dimorphism of NAFLD, being more prevalent in males than in females (40) . NAFLD is commonly associated with all of the component features of the metabolic syndrome, which, in turn, can increase the risk of development and progression of NAFLD. Bariatric surgery not only improves features of the metabolic syndrome, but also ameliorates NAFLD, NASH, and NASH fibrosis in patients with morbid obesity (41) (42) (43) (44) (45) , but the underlying mechanisms remain unknown. Experimental and clinical evidence suggest a link between obesity-associated NAFLD and circulating ghrelin isoforms (12, (16) (17) (18) (19) . In a previous study, we found a progressive elevation in plasma acylated ghrelin and a decrease in plasma desacyl ghrelin as the number of components of the metabolic syndrome increased in patients with obesity, suggesting a potential role of both ghrelin isoforms in the pathogenesis and treatment of the metabolic syndrome (19) . Moreover, the human liver synthesizes ghrelin, and a slight increase in ghrelin expression has been reported in patients with NASH (46). In the current study, we found that patients with obesity and NAFLD exhibited lower plasma desacyl ghrelin levels with an increase in the acylated/desacyl ghrelin ratio in parallel to the worsening of liver function, which is in agreement with previous reports (12, 25, 31, 47) . Accordingly, a reduction in circulating g-GT was observed in patients with morbid obesity after RYGB, with postsurgical desacyl and acylated ghrelin concentrations being negatively correlated with g-GT levels. We were not able to detect changes in the hepatic ghrelin, but a marked upregulation of the ghrelin-acylating enzyme GOAT was observed in liver samples of patients with obesity and T2D. Interestingly, the proinflammatory TNF-a, also increased in the circulation and liver of patients with obesity and T2D, upregulated MBOAT4 expression, suggesting that ghrelin acylation is activated during liver injury induced by TNF-a. Thus, it seems plausible that the decrease in circulating acylated ghrelin after RYGB might reflect the improvement in insulin sensitivity and the mitigation of hepatic inflammation after bariatric surgery.
The members of the TNF protein superfamily are among the best characterized inducers of hepatocyte cell death, a hallmark of liver damage (9, 10) . Several mechanisms have been proposed to cause hepatocyte demise, including apoptosis, defective autophagy, necrosis, and/or pyroptosis (9, 10). We provide evidence for an overexpression of TNF-a and death receptors TNF-R1 and DR3 as well as an activation of the apoptosis extrinsic pathway in the liver of patients with morbid obesity and T2D, confirming the role of insulin resistance as an independent risk factor for the onset of liver injury (48) . Interestingly, acylated ghrelin and desacyl ghrelin inhibited the TNF-a-induced cleavage of caspase-8 and caspase-3 and hepatocyte apoptosis in human HepG2 hepatocytes (Fig. 7) . This is consistent with our previous observation (31) that ghrelin isoforms reduced this proapoptotic signaling triggered by TNF-a in human visceral adipocytes. Analogously, Mao et al. (49) recently revealed that ghrelin treatment attenuates the hepatocyte apoptosis induced by palmitic acid and LPS, two factors involved in liver injury associated with hyperlipidemia and septic shock, respectively, through the inactivation of proinflammatory c-Jun N-terminal kinase and P38 MAPK pathways and caspase-3. In line with this observation, both the administration of ghrelin to C57BL6/J mice fed a high-fat diet (50) and the administration of growth hormone-releasing peptide-2, a ghrelin receptor agonist, to LPS-treated rats (51) prevents the increase in transaminases and downregulates hepatic TNF-a expression, confirming the hepaticprotective role of ghrelin in response to lipoxicity and sepsis. These findings suggest that ghrelin acts as a hepatocyte survival factor by inhibiting inflammation and apoptosis in several liver diseases, including NAFLD.
Under physiological conditions, autophagy regulates hepatic lipid metabolism through the breakdown of lipid droplets and its mobilization to lysosomes (11) . However, autophagic flux is decreased (13, 52, 53) or unchanged (12) during the ongoing NAFLD, favoring an abnormal hepatic steatosis. Impairment of liver autophagy in experimental models of NAFLD has been also related to changes in insulin signaling (54), a potent inhibitor of autophagy. The patients with prediabetes of our cohort showed an upregulation of autophagy in spite of their hyperinsulinemia, evidenced by an increased LC3B-II/I ratio, whereas no changes were observed in T2D patients. These findings point to a compromised hepatic autophagy in patients with insulin resistance that may reflect the increased cell death of hepatocytes (11) . In this regard, a defective autophagy underlies several liver disorders, including NAFLD, and leaves hepatocytes vulnerable to stressors and unable to accommodate the extreme energetic demands, ultimately leading to liver injury (9, 11, 55) . Experimental evidence has revealed that acylated and desacyl ghrelin enhance autophagy in rat hepatocytes contributing to NAFLD amelioration (12) . Moreover, in animal models of acute hepatitis and liver fibrosis, ghrelin induces hepatic autophagy to prevent further cell injury (50) . Our data indicate that the regulation of autophagy in human HepG2 hepatocytes in several aspects differs from experimental reports. We showed that mTOR activation triggered by acylated ghrelin inhibits basal autophagy, whereas AMPK activation by desacyl ghrelin stimulates basal autophagy in human hepatocytes. Thus, under basal conditions, ghrelin isoforms oppositely regulate lipophagy, without inducing autophagic cell death. Analogously, opposite effects of ghrelin isoforms on hepatic glucose metabolism have been reported (56) . Interestingly, acylated and desacyl ghrelin blunted TNFa-induced autophagy in human hepatocytes (Fig. 7) , a protective action that is also observed in human visceral adipocytes (31) . Inasmuch as hepatic autophagy is required to maintain energy homeostasis, it seems plausible that desacyl ghrelin-induced basal autophagy constitutes an adaptive response for lipid mobilization to obtain ATP, whereas acylated ghrelin acts as a protective agent against injury induced by TNF-a during an inflammatory state.
The innate alarmin HMGB1 plays an important role in the activation of pyroptosis following liver injury. Under physiological conditions, HMGB1 is a nuclear factor that maintains nuclear DNA structure and function (15) . However, several liver injuries such as heat shock (57), CCl 4 (58), acetaminophen (59), or infectious peritonitis (59), induce HMGB1 translocation from the nuclei to the cytoplasm for being secreted to the extracellular space. Extracellular HMGB1 binds its receptors TLR4 and RAGE, activating the NLRP3 inflammasome and caspase-1, ultimately leading to hepatocyte pyroptotic cell death (Fig. 7) (57) . The antidiabetic drug metformin directly binds HMGB1 and inhibits its inflammatory responses in a model of acetaminopheninduced acute liver injury (60) , suggesting that this process might be reversible. In this study, we showed that insulin resistance strongly influenced hepatic expression of HMGB1, TLR4, and RAGE as well as caspase-1 cleavage in patients with morbid obesity. Our data revealed that insulin and MCM-LPS triggered HMGB1 translocation from the hepatocyte nucleus to cytosolic compartments resembling lysosomes, the organelles involved in HMGB1 secretion to the extracellular milieu (38) . Moreover, both insulin and TNF-a, one of the most abundant cytokines produced by LPS-activated macrophages, increased the expression of HMGB1 in HepG2 hepatocytes at the highest tested concentrations. Taken together, our findings indicate that hepatic HMGB1 expression and secretion is altered in insulin-resistant states, contributing to the progression of NAFLD to NASH through the activation of pyroptosis. Interestingly, ghrelin acts as an anti-inflammatory factor in experimental sepsis (61) and myocardial ischemia/reperfusion injury (62) by inhibiting HMGB1. Accordingly, we found that both ghrelin isoforms inhibited basal and TNF-a-induced HMGB1 expression and blocked caspase-1 autocatalytic activation induced by TNF-a (Fig. 7) , supporting their protective role against pyroptosis also in hepatocytes.
One limitation of the current study is that larger cohorts will be necessary to increase the statistical power and, hence, establish the specific contribution of acylated and desacyl ghrelin in the progression of NAFLD to NASH in patients with morbid obesity. Nonetheless, we stress that our patients were carefully selected to avoid confounding factors and had a detailed clinical, biochemical and metabolic characterization that included anthropometric examination, body composition assessment, ultrasound echography, and a liver biopsy for diagnosis of NAFLD to perform a robust analysis.
In conclusion, in this study we show that the beneficial effects of ghrelin isoforms on NAFLD are mediated by their ability to reduce TNF-a-induced hepatocyte apoptosis, pyroptosis, and autophagy. The imbalance of ghrelin isoforms and TNF-a in the insulin-resistant state may contribute to the increased hepatocyte cell death found in T2D.
